As expected (and as previously discussed on this site), Amgen has submitted a supplemental Biologics Licensing Application (sBLA) for denosumab (Xgeva®) for the prevention or the delay of the spread of prostate cancer to bone in men with castrate-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Amgen, bone metastasis-free, castration-resistant, denosumab, outcome, survival, Xgeva | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 